MarketCap
Facebook
X
Telegram
BioLineRx Ltd. ROCE Ratio | BLRX
Annual ROCE Ratio BioLineRx Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -35.74 | -86.84 | -235.06 | -44.38 | -34.57 | -104.07 | -67.58 | -51.75 | -46.53 | -46.81 | -33.63 | -47.65 | -103.99 | -122.1 | -68.24 |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -33.63 | -235.06 | -75.26 |
Quarterly ROCE Ratio BioLineRx Ltd.
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -147.86 | -347.17 | -360.21 | -281.37 | -277.88 | -54.94 | -33.62 | -33.62 | -33.62 | -33.62 | -33.62 | -33.62 | -45.84 | -37.84 | -37.84 | -37.84 | -46.88 | -33.39 | -33.39 | -33.39 | -12.13 | - | - | - | -12.22 | - | - | - | -9.04 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -9.04 | -360.21 | -87.43 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Repare Therapeutics
RPTX
|
-61.88 | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
222.79 | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
-261.49 | - | - | $ 26.8 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
-141.18 | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
-159.95 | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
-129.64 | - | - | $ 13 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
289.47 | - | - | $ 24.9 M | USA |
 |
Brickell Biotech
BBI
|
-64.05 | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
-175.6 | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
-29.63 | - | - | $ 8.86 M | Canada |
 |
Generation Bio Co.
GBIO
|
-165.18 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
74.33 | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
-41.99 | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
-71.67 | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
-102.25 | $ 4.21 | 4.99 % | $ 653 M | USA |
 |
AbbVie
ABBV
|
-461.01 | $ 291.22 | 1.06 % | $ 515 B | USA |
 |
22nd Century Group
XXII
|
-67.97 | $ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
-1.91 | $ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
14.56 | $ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
Theratechnologies
THTX
|
49.6 | - | - | $ 83.9 M | Canada |
 |
Exelixis
EXEL
|
35.76 | $ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Geron Corporation
GERN
|
-14.94 | $ 0.99 | 3.97 % | $ 660 M | USA |
 |
Gilead Sciences
GILD
|
44.14 | $ 166.9 | -0.4 % | $ 208 B | USA |
 |
Grifols, S.A.
GRFS
|
6.19 | $ 8.46 | -0.12 % | $ 5.75 B |  Spain |
 |
Alnylam Pharmaceuticals
ALNY
|
14.33 | $ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
InflaRx N.V.
IFRX
|
-43.45 | $ 1.31 | -3.69 % | $ 88.1 M |  Germany |
 |
INmune Bio
INMB
|
-197.97 | $ 1.12 | -4.68 % | $ 27.7 M | USA |
 |
Insmed Incorporated
INSM
|
-69.43 | $ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
14.23 | $ 274.89 | 0.95 % | $ 662 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
-186.76 | - | -3.76 % | $ 3.47 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
-82.2 | $ 1.02 | 3.75 % | $ 235 M | USA |
 |
BioVie
BIVI
|
-95.03 | $ 1.33 | 9.92 % | $ 1.96 M | USA |
 |
Longeveron
LGVN
|
-377.18 | $ 1.82 | 6.43 % | $ 32 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-53.64 | - | 3.16 % | $ 1.9 M | USA |
 |
TCR2 Therapeutics
TCRR
|
-108.97 | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-52.09 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mustang Bio
MBIO
|
-25.13 | $ 0.39 | 0.15 % | $ 1.91 M | USA |
|
TFF Pharmaceuticals
TFFP
|
-228.86 | - | -60.05 % | $ 125 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 1.63 | 1.87 % | $ 2.68 M |  Israel |
 |
Mesoblast Limited
MESO
|
-13.2 | $ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Mirum Pharmaceuticals
MIRM
|
-3.47 | $ 93.81 | 0.28 % | $ 4.71 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-580.3 | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-13.43 | - | - | $ 521 M | USA |
 |
Codexis
CDXS
|
-82.6 | $ 1.09 | 6.37 % | $ 95 M | USA |